-
1Academic Journal
Source: Urology Herald; Том 10, № 4 (2022); 155-164 ; Вестник урологии; Том 10, № 4 (2022); 155-164 ; 2308-6424 ; 10.21886/2308-6424-2022-10-4
Subject Terms: биомаркеры, bladder cancer, non-muscle-invasive cancer, transurethral resection, BCG therapy, biomarkers, рак мочевого пузыря, немышечно-инвазивный рак, трансуретральная резекция, БЦЖ-терапия
File Description: application/pdf
Relation: https://www.urovest.ru/jour/article/view/615/424; Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Seisen T, Soukup V, Sylvester RJ. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81(1):75-94. https://doi.org/10.1016/j.eururo.2021.08.010; Balasubramanian A, Gunjur A, Weickhardt A, Papa N, Bolton D, Lawrentschuk N, Perera M. Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage. World J Urol. 2022;40(5):1111-1124. https://doi.org/10.1007/s00345-021-03908-x; Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180-3. https://doi.org/10.1016/s0022-5347(17)58737-6; Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247-56. https://doi.org/10.1016/j.eururo.2009.04.038; Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, Mason MD. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88(3):209-16. https://doi.org/10.1046/j.1464-410x.2001.02306.x; Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67(6):1216-23. https://doi.org/10.1016/j.urology.2005.12.014; Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93(4):485-90. https://doi.org/10.1111/j.1464-410x.2003.04655.x; Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003 Jan;169(1):90-5. https://doi.org/10.1097/01.ju.0000039680.90768.b3; Sylvester RJ, van der MEIJDEN AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964-70. https://doi.org/10.1097/01.ju.0000034450.80198.1c; Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer--a current perspective. Nat Rev Urol. 2014;11(3):153-62. https://doi.org/10.1038/nrurol.2014.15; Savic S, Zlobec I, Thalmann GN, Engeler D, Schmauss M, Lehmann K, Mattarelli G, Eichenberger T, Dalquen P, Spieler P, Schoenegg R, Gasser TC, Sulser T, Forster T, Zellweger T, Casella R, Bubendorf L. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. Int J Cancer. 2009;124(12):2899-904. https://doi.org/10.1002/ijc.24258; Kamat AM, Dickstein RJ, Messetti F, Anderson R, Pretzsch SM, Gonzalez GN, Katz RL, Khanna A, Zaidi T, Wu X, Grossman HB, Dinney CP. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial. J Urol. 2012;187(3):862-7. https://doi.org/10.1016/j.juro.2011.10.144; Kamat AM, Willis DL, Dickstein RJ, Anderson R, Nogueras-González G, Katz RL, Wu X, Barton Grossman H, Dinney CP. Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. BJU Int. 2016;117(5):754-60. https://doi.org/10.1111/bju.13186; Kamat AM, Briggman J, Urbauer DL, Svatek R, Nogueras González GM, Anderson R, Grossman HB, Prat F, Dinney CP. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin. Eur Urol. 2016;69(2):197-200. https://doi.org/10.1016/j.eururo.2015.06.023; Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, Abbou CC, Chopin DK. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol. 2002 Jan;167(1):364-7. PMID: 11743357; Watanabe E, Matsuyama H, Matsuda K, Ohmi C, Tei Y, Yoshihiro S, Ohmoto Y, Naito K. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother. 2003 Aug;52(8):481-6. https://doi.org/10.1007/s00262-003-0384-9; de Reijke TM, de Boer EC, Kurth KH, Schamhart DH. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol. 1996;155(2):477-82. PMID: 8558640; Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol. 2000;164(6):2129-33. PMID: 11061941; Sagnak L, Ersoy H, Ozok U, Senturk B, Ercil H, Bahar G, Ozturk E. Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus Calmette-Guérin treatment in non-muscle-invasive bladder tumors. Clin Genitourin Cancer. 2009;7(2):E16-23. https://doi.org/10.3816/CGC.2009.n.016; Luo Y, Han R, Evanoff DP, Chen X. Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells. Clin Exp Immunol. 2010;160(3):359-68. https://doi.org/10.1111/j.1365-2249.2010.04105.x; Cai T, Nesi G, Mazzoli S, Meacci F, Tinacci G, Luciani LG, Ficarra V, Malossini G, Bartoletti R. Prediction of response to bacillus Calmette-Guérin treatment in non-muscle invasive bladder cancer patients through interleukin-6 and interleukin-10 ratio. Exp Ther Med. 2012;4(3):459-464. https://doi.org/10.3892/etm.2012.634; Atkins H, Davies BR, Kirby JA, Kelly JD. Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy. Br J Cancer. 2003;89(12):2312-9. https://doi.org/10.1038/sj.bjc.6601474; Pichler R, Fritz J, Zavadil C, Schäfer G, Culig Z, Brunner A. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer. Oncotarget. 2016;7(26):39916-39930. https://doi.org/10.18632/oncotarget.9537; Nunez-Nateras R, Castle EP, Protheroe CA, Stanton ML, Ocal TI, Ferrigni EN, Ochkur SI, Jacobsen EA, Hou YX, Andrews PE, Colby TV, Lee NA, Lee JJ. Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder. Urol Oncol. 2014;32(1):45.e23-30. https://doi.org/10.1016/j.urolonc.2013.06.008; Racioppi M, Di Gianfrancesco L, Ragonese M, Palermo G, Sacco E, Bassi PF. Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer? Int Braz J Urol. 2019;45(2):315-324. https://doi.org/10.1590/S1677-5538.IBJU.2018.0249; Akan S, Ediz C, Sahin A, Tavukcu HH, Urkmez A, Horasan A, Yilmaz O, Verit A. Can the systemic immune inflammation index be a predictor of BCG response in patients with high-risk non-muscle invasive bladder cancer? Int J Clin Pract. 2021;75(4):e13813. https://doi.org/10.1111/ijcp.13813; Elsawy AA, Abol-Enein H, Laymon M, Ahmed AE, Essam A, Hamam ET, Zidan AA, Zahran MH, Shokeir AA, Awadalla A. Predictive value of immunological markers after bacille Calmette-Guérin induction in bladder cancer. BJU Int. 2022;130(4):444-453. https://doi.org/10.1111/bju.15582; Palou J, Algaba F, Vera I, Rodriguez O, Villavicencio H, Sanchez-Carbayo M. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin. Eur Urol. 2009;56(5):829-36. https://doi.org/10.1016/j.eururo.2008.09.062; Bertz S, Otto W, Denzinger S, Wieland WF, Burger M, Stöhr R, Link S, Hofstädter F, Hartmann A. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. Eur Urol. 2014;65(1):218-26. https://doi.org/10.1016/j.eururo.2012.05.033; Malmström PU, Hemdan T, Segersten U. Validation of the ezrin, CK20, and Ki-67 as potential predictive markers for BCG instillation therapy of non-muscle-invasive bladder cancer. Urol Oncol. 2017;35(8):532.e1-532.e6. https://doi.org/10.1016/j.urolonc.2017.03.010; Park J, Song C, Shin E, Hong JH, Kim CS, Ahn H. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy? Urol Oncol. 2013;31(6):849-56. https://doi.org/10.1016/j.urolonc.2011.06.004; Ji M, Liu Y, Li Q, Li XD, Zhao WQ, Zhang H, Zhang X, Jiang JT, Wu CP. PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. J Transl Med. 2015;13:5. https://doi.org/10.1186/s12967-014-0373-0; Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24(2):207-12. https://doi.org/10.1016/j.coi.2011.12.009; Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261-8. https://doi.org/10.1038/85330; Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol. 2015;68(2):267-79. https://doi.org/10.1016/j.eururo.2015.02.032; Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558-62. https://doi.org/10.1038/nature13904; Wankowicz SAM, Werner L, Orsola A, Novak J, Bowden M, Choueiri TK, de Torres I, Morote J, Freeman GJ, Signoretti S, Bellmunt J. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. J Urol. 2017;198(4):817-823. https://doi.org/10.1016/j.juro.2017.04.102; Kamat AM, Li R, O'Donnell MA, Black PC, Roupret M, Catto JW, Comperat E, Ingersoll MA, Witjes WP, McConkey DJ, Witjes JA. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. Eur Urol. 2018;73(5):738-748. https://doi.org/10.1016/j.eururo.2017.10.003; Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-5; discussion 475-7. https://doi.org/10.1016/j.eururo.2005.12.031; Fernandez-Gomez J, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Hernandez R, Madero R, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Isorna S, Rabadan M, Astobieta A, Montesinos M, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA; Club Urológico Español de Tratamiento Oncológico (CUETO). Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol. 2008;53(5):992-1001. https://doi.org/10.1016/j.eururo.2007.10.006; Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Ojea A, Portillo J, Montesinos M, Gonzalez M, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Isorna S, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA; Club Urológico Español de Tratamiento Oncológico. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. Eur Urol. 2011;60(3):423-30. https://doi.org/10.1016/j.eururo.2011.05.033; Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Montesinos M, Isorna S, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195-203. https://doi.org/10.1016/j.juro.2009.07.016; https://www.urovest.ru/jour/article/view/615
-
2Academic Journal
Authors: Zamyatin, A. V., Mager, V. O., Orlov, A. S., Il’in, K. A., Zavatskiy, S. E., Kovalenko, D. A., Shcheglova, V. P., Berzin, S. A., Zyryanov, A. V., Замятин, А. В., Магер, В. О., Орлов, А. С., Ильин, К. А., Завацкий, С. Е., Коваленко, Д. А., Щеглова, В. П., Берзин, С. А., Зырянов, А. В.
Subject Terms: ADJUVANT INTRAVESICAL CHEMOTHERAPY, HYDROGEL, TITANIUM GLYCEROSOLVATE AQUACOMPLEX, INTRAVESICAL BCG, HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER, PROPENSITY SCORE MATCHING, PSEUDO RANDOMIZATION, АДЪЮВАНТНАЯ ВНУТРИПУЗЫРНАЯ ХИМИОТЕРАПИЯ, ГИДРОГЕЛЬ, АКВАКОМПЛЕКС ГЛИЦЕРОСОЛЬВАТА ТИТАНА, ВНУТРИПУЗЫРНАЯ БЦЖ-ТЕРАПИЯ, НЕМЫШЕЧНО-ИНВАЗИВНЫЙ РАК МОЧЕВОГО ПУЗЫРЯ ВЫСОКОГО РИСКА, ПСЕВДОРАНДОМИЗАЦИЯ
File Description: application/pdf
Relation: Scopus; http://elib.usma.ru/handle/usma/7178
Availability: http://elib.usma.ru/handle/usma/7178
-
3Academic Journal
Authors: A. V. Zamyatin, V. O. Mager, A. S. Orlov, K. A. Il'in, S. E. Zavatskiy, D. A. Kovalenko, V. P. Shcheglova, S. A. Berzin, A. V. Zyryanov, А. В. Замятин, В. О. Магер, А. С. Орлов, К. A. Ильин, С. Е. Завацкий, Д. А. Коваленко, В. П. Щеглова, С. А. Берзин, А. В. Зырянов
Source: Cancer Urology; Том 16, № 3 (2020); 126-134 ; Онкоурология; Том 16, № 3 (2020); 126-134 ; 1996-1812 ; 1726-9776
Subject Terms: псевдорандомизация, hydrogel, titanium glycerosolvate aquacomplex, intravesical BCG, high risk non-muscle invasive bladder cancer, propensity score matching, pseudo randomization, гидрогель, аквакомплекс глицеросольвата титана, внутрипузырная БЦЖ-терапия, немышечно-инвазивный рак мочевого пузыря высокого риска
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1308/1199; https://oncourology.abvpress.ru/oncur/article/view/1308/1238; Babjuk M., Burger M., Comperat E.M. et al. European Association of Urology Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ): 2019 update. Eur Urol 2019;76(5):639-57. DOI:10.1016/j.eururo.2019.08.016.; Chang S.S., Boorjian S.A., Chou R. et al. Diagnosis and treatment of non-muscle invasive bladder Cancer: AUA/SUO guideline. J Urol 2016;196 (4):1021-9. DOI:10.1016/j.juro.2016.06.049.; Злокачественные опухоли (спецвыпуск журнала): практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. Под ред. В.М. Моисеенко. М.: Общероссийская общественная организация «Российское общество клинической онкологии», 2018. 704 с.; Bohle A., Jocham D., Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169(1):90-5. DOI:10.1097/01.ju.0000039680.90768.b3.; Sylvester R.J., Brausi M.A., Kirkels W.J. et al. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57(5):766-73. DOI:10.1016/j.eururo.2009.12.024.; Fernandez-Gomez J., Madero R., Solsona E. et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 2009;182(5):2195-203. DOI:10.1016/j.juro.2009.07.016.; Солодова А.А. БЦЖ-терапия в России: инстинкт самосохранения и министерские документы. Урология сегодня 2019;2(52). Доступно по: http://www.urotoday.ru/article/id-171.; Davies B.J., Hwang T.J., Kesselheim A.S. Ensuring access to injectable generic drugs: the case of intravesical BCG for bladder cancer. N Engl J Med 2017;376(15):1401-3. DOI:10.1056/NEJMp1615697.; Зорина М.М., Кульчавеня Е.В., Холто-бин Д.П. Правовые основы BCG-терапии для лечения рака мочевого пузыря в условиях муниципальных поликлиник. Туберкулез и болезни легких 2016;94(10):55-61.; Oddens J., Brausi M., Sylvester R. et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63(3):462-72. DOI:10.1016/j.eururo.2012.10.039.; Sylvester R.J., Oosterlinck W., van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a metaanalysis of published results of randomized clinical trials. J Urol 2004;171 (6 Pt 1):2186-90. DOI:10.1097/01.ju.0000125486.92260.b2.; Friedrich M.G., Pichlmeier U., Schwaibold H. et al. Long-term intravesical adjuvant chemotherapy further reduces the recurrence rate compared with shortterm intravesical chemotherapy and shortterm therapy with bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 2007;52(4):1123-29. DOI:10.1016/j.eururo.2007.02.063.; Veeratterapillay R., Heer R., Johnson M.I. et al. High-risk non-muscle-invasive bladder cancer-therapy options during intravesical BCG shortage. Curr Urol Rep 2016;17(9):68. DOI:10.1007/s11934-016-0625-z.; Новые технологии в медицине. Тизоль: сборник научных статей. Под ред. В.И. Шилко. Екатеринбург: УГМА, 2003. 152 с. [New technologies in medicine. Tizol: collection of research articles. Ed.: V.I. Shilko. Yekaterinburg: UGMA, 2003. 152 p. (In Russ.)].; Высокоэффективные технологии в медицине. Тизоль: сборник материалов межобластной конференции (15 марта 2001 г.). Екатеринбург: УГМА. 80 c.; Замятин А.В., Магер В.О., Орлов А.С. и др. Отдаленные результаты адъювантной внутрипузырной химиотерапии с аквакомплексом глицеросольвата титана у больных немышечно-инвазив-ным раком мочевого пузыря высокого риска. Онкоурология 2019;15(1): 92-100.; Rosenbaum P.R., Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70(1):41-55.; Гржибовский А.М., Иванов С.В., Горбатова М.А., Дюсупов А.А. Псевдорандомизация (propensity score matching) как современный статистический метод устранения систематических различий сравниваемых групп при анализе количественных исходов в обсервационных исследованиях. Экология человека 2016;(7):51-60.; EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2020.; Flaig T.W., Spiess P.E., Agarwal N. et al. NCCN Clinical Practice Guidelines in Oncology Bladder Cancer Version 3, 2019. Available at: https://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf. Accessed July, 2019.; Martmez-Pineiro J.A., Leon J. J., Martmez-Pineiro L. Jr et al. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol 1990;143(3):502-6. DOI:10.1016/s0022-5347(17)40002-4.; Chou R., Selph S., Buckley D. et al. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol 2017;197(5):1189-99. DOI:10.1016/j.juro.2016.12.090.; Malmstrom P.U., Sylvester R.J., Crawford D.E. et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscleinvasive bladder cancer. Eur Urol 2009;56(2):247-56. DOI:10.1016/j.eururo.2009.04.038.; Arends T.J., van der Heijden A.G., Witjes J.A. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. J Urol 2014;192 (3):708-13. DOI:10.1016/j.juro.2014.03.101.; Di Stasi S.M., Valenti M., Verri C. et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial nonmuscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol 2011;12(9):871-9. DOI:10.1016/S1470-2045(11)70190-5.; Bendary L., Khalil S., Shahin A., Nawar N. 1655 intravesical gemcitabine versus bacillus Calmette-Guerin (BCG) in treatment of nonmuscle invasive bladder cancer: short term comparative study. J Urol 2011;185:e664-5.; Barlow L.J., Mckiernan J.M., Benson M.C. Longterm survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy. J Urol 2013;189(3):834-9. DOI:10.1016/j.juro.2012.10.068.; Kamat A.M., Colombel M., Sundi D. et al. BCG-unresponsive non-muscle-invasive bladder cancer: definition, treatment options and management recommendations from the International Bladder Cancer Group (IBCG). Nat Rev Urol 2017;14(4):244-55. DOI:10.1038/nrurol.2017.16.; https://oncourology.abvpress.ru/oncur/article/view/1308
-
4Academic Journal
Authors: Zamyatin, A. V., Mager, V. O., Orlov, A. S., Ilyin, K. A., Zavatskiy, S. E., Kovalenko, D. A., Shcheglova, V. P., Berzin, S. A., Zyryanov, A. V., Замятин, А. В., Магер, В. О., Орлов, А. С., Ильин, К. А., Завацкий, С. Е., Коваленко, Д. А., Щеглова, В. П., Берзин, С. А., Зырянов, А. В.
Subject Terms: ADJUVANT INTRAVESICAL CHEMOTHERAPY, PENETRANT, TITANIUM GLYCEROSOLVATE AQUACOMPLEX, HIGH RISK NON-MUSCLE-INVASIVE BLADDER CANCER, BCG THERAPY, АДЪЮВАНТНАЯ ВНУТРИПУЗЫРНАЯ ХИМИОТЕРАПИЯ, ПЕНЕТРАНТ, АКВАКОМПЛЕКС ГЛИЦЕРОСОЛЬВАТА ТИТАНА, НЕМЫШЕЧНОИНВАЗИВНЫЙ РАК МОЧЕВОГО ПУЗЫРЯ ВЫСОКОГО РИСКА, БЦЖ-ТЕРАПИЯ
File Description: application/pdf
Relation: Scopus; http://elib.usma.ru/handle/usma/7124
Availability: http://elib.usma.ru/handle/usma/7124
-
5Academic Journal
Authors: A. V. Zamyatin, V. O. Mager, A. S. Orlov, K. A. Ilyin, S. E. Zavatskiy, D. A. Kovalenko, V. P. Shcheglova, S. A. Berzin, A. V. Zyryanov, А. В. Замятин, В. О. Магер, А. С. Орлов, К. А. Ильин, С. Е. Завацкий, Д. А. Коваленко, В. П. Щеглова, С. А. Берзин, А. В. Зырянов
Source: Cancer Urology; Том 15, № 1 (2019); 92-100 ; Онкоурология; Том 15, № 1 (2019); 92-100 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2019-15-1
Subject Terms: БЦЖ-терапия, penetrant, titanium glycerosolvate aquacomplex, high risk non-muscle-invasive bladder cancer, BCG therapy, пенетрант, аквакомплекс глицеросольвата титана, немышечноинвазивный рак мочевого пузыря высокого риска
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/857/832; Sylvester R.J., van der Meijden A.P., Oosterlinck W. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49(3):466-5. DOI:10.1016/j.eururo.2005.12.031. PMID: 16442208.; Babjuk M., Bohle A., Burger M. et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017;71(3):447—61. DOI:10.1016/j.eururo.2016.05.041. PMID: 27324428.; Malmstrom P.U., Sylvester R.J., Crawford D.E. et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette— Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009;56(2):247-56. DOI:10.1016/j.eururo.2009.04.038. PMID: 19409692.; Ojea A., Nogueira J.L., Solsona E. et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: lowdose bacillus Calmette—Guerin (27 mg) versus very low-dose bacillus Calmette—Guerin (13.5 mg) versus mitomycin C. Eur Urol 2007;52:1398.; Oddens J., Brausi M., Sylvester R. et al. Final results of an EORTC-GU Cancer Group randomized study of maintenance bacillus Calmette—Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63(3):462—72. DOI:10.1016/j.eururo.2012.10.039. PMID: 23141049.; Sylvester R.J., Oosterlinck W., van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a metaanalysis of published results of randomized clinical trials. J Urol 2004;171(6 Pt 1): 2186-90. PMID: 15126782.; Friedrich M.G., Pichlmeier U., Schwaibold H. et al. Long-term intravesical adjuvant chemotherapy further reduces the recurrence rate compared with shortterm intravesical chemotherapy and shortterm therapy with bacillus Calmette— Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 2.007;52(4):1123—29. DOI:10.1016/j.eururo.2007.02.063. PMID: 17383080.; Gan Y., Wientjes M.G., Badalament R.A., Au J.L. Pharmacodynamics of doxorubicin in human bladder tumors. Clin Cancer Res 1996;2(8):1275—83. PMID: 9816297.; GuhaSarkar S., Banerjee R. Intravesical drug delivery: challenges, current status, opportunities and novel strategies. J Control Release 2010;148(2):147—59. DOI:10.1016/j.jconrel.2010.08.031. PMID: 20831887.; Kuroda M., Niijima T., Kotake T. et al. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer — The 6th Trial of Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose 20 mg/40 ml, 30 mg/40 ml, 40 mg/40 ml. Eur Urol 2004;45(5):600—5. DOI:10.1016/j.euru-ro.2003.12.010. PMID: 15082202.; Babjuk M., Burger M., Zigeuner R. et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64(4):639—53. DOI:10.1016/j.eururo.2013.06.003. PMID: 23827737.; American Urological Association. Guidelines for the management of non-muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. Linthicum, MD: AUA; 2007.; Paroni R., Salonia A., Lev A. et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol 2001;52(3):273—8. PMID: 11560559.; Di Stasi S.S., Ridel C. Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer. World J Urol 2009;27(3):325—30. DOI:10.1007/s00345-009-0389-x. PMID: 19234707.; Colombo R., Brausi M., Da Pozzo L. et al. Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. A pilot study on marker lesion. Eur Urol 2001;39(1):95—100. DOI:10.1159/000052419. PMID: 11173946.; Ueda K., Sakagami H., Masui Y., Okamu-ra T. Single instillation of hydroxypropyl-cellulose-doxorubicin as treatment for superficial bladder cancer. Cancer Chemother. Pharmacol 1994;35:81—3. PMID: 7994793.; Eroglu M., Irmak S., Acar A., Denkba§ E.B. Design and evaluation of a mucoadhesive therapeutic agent delivery system for postoperative chemotherapy in superficial bladder cancer. Int J Pharmacol 2002;235(1 —2):51 —9. PMID: 11879739.; Tyagi P., Li Z., Chancellor M. et al. Sustained intravesical drug delivery using thermosensitive hydrogel. Pharm Res 2004;21(5):832—7. PMID: 15180342.; Chatta D., Cottrell L., Burnett B. et al. The use of water-soluble mucoadhesive gels for the intravesical delivery of epirubi-cin to the bladder for the treatment of non-muscle-invasive bladder cancer. J Pharm Pharmacol 2015;67(10):1355—62. DOI:10.1111/jphp.12441. PMID: 26076758.; Men K., Liu W. Delivering instilled hydrophobic drug to the bladder by cationic nanoparticle and thermosensitive hydrogel composite system. Nanoscale 2012;4:6425—33.; Lu S., Neoh K.G., Kang E.T. et al. Muco-adhesive polyacriamide nanogel as a potential hydrophobic drug carrier for intravesical bladder cancer therapy. Eur J Pharm Sci 2015;72:57—68. DOI:10.1016/j.ejps.2015.03.006. PMID: 25772330.; Zhang Q., Neoh K.G., Xu L. et al. Functionalized mesoporous silica nanoparticles with mucoadhesive and sustained drug release properties for potential bladder cancer therapy. Langmuir 2014;30(21):6151— 61. DOI:10.1021/la500746e. PMID: 24824061.; Lu Z., Yeh T.K., Tsai M. et al. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin Cancer Res 2004;10(22):7677—84. DOI:10.1158/1078-0432.CCR-04-1443. PMID: 15570001.; Новые технологии в медицине. Тизоль: сборник научных статей. Под ред. В.И. Шилко. Екатеринбург: УГМА, 2003. 152 с. [New technologies in medicine. Tisolum: Collection of scientific articles. Ed. V.I. Shilko. Ekaterinburg: UGMA, 2003. 152 p. (In Russ.)].; Высокоэффективные технологии в медицине. Тизоль: сборник материалов межобластной конференции (15 марта 2001 г.). Екатеринбург: УГМА. 80 c.; Замятин А.В., Берзин С.А. Адъювантная внутрипузырная терапия при поверхностном раке мочевого пузыря у больных промежуточной группы риска с использованием традиционной методики инстилляций и с применением 40 % водного раствора Тизоля. Материалы XII Российского онкологического конгресса. М.: Издательская группа ГУ РОНЦ им. Н.Н. Блохина РАМН, 2008. С. 203.; Берзин С.А., Замятин А.В. Способ послеоперационной терапии немышеч-но-инвазивного рака мочевого пузыря. Патент России № 2443423, 27.02.2012. Бюл. № 6.; National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CT-CAE_4.03_2010-06-14_QuickReference_5x7.pdf.; Babjuk M. Guidelines on Non-muscle-invasive bladder cancer (Ta, T1 and CIS), 2018. Edn presented at the 33nd EAU Annual Congress Copenhagen 2018. Available at: http://uroweb.org/guideline/non-mus-cle-invasive-bladder-cancer/.; Mostafid A.H., Palou Redorta J., Sylvester R., Witjes J.A. Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette—Guerin. Eur Urol 2015;67(3):359—60. DOI:10.1016/j.euru-ro.2014.11.031. PMID: 25442053.; Steers W.D. Falling short: causes and implications of drug shortages in the United States. J Urol 2014;192(5):1315—7. DOI:10.1016/j.juro.2014.09.003. PMID: 25218647.; Урология сегодня, 2018, № 2 (52). Available at: http://www.urotoday.ru.; Veeratterapillay R., Heer R., Johnson M.I. et al. High-risk non-muscle-invasive bladder cancer-therapy options during intravesical BCG shortage. Curr Urol Rep 2016;17(9):68. DOI:10.1007/s11934-016-0625-z. PMID: 27492610.; https://oncourology.abvpress.ru/oncur/article/view/857
-
6Academic Journal
Authors: Fedevych, V.S.
Source: Урологія; Том 23, № 3 (2019)
Урология; Том 23, № 3 (2019)
Urology; Том 23, № 3 (2019)Subject Terms: 03 medical and health sciences, 0302 clinical medicine, рак сечового міхура, фактор росту ендотелію судин, фактор некрозу пухлини, поліморфізм, внутрішньоміхурова БЦЖ-терапія, рак мочевого пузыря, фактор роста эндотелия сосудов, фактор некроза опухоли, полиморфизм, внутрипузырная БЦЖ-терапия, bladder cancer, vascular endothelial growth factor, tumor necrosis factor, polymorphism, intravesical BCG therapy, 6. Clean water, 3. Good health
File Description: application/pdf
-
7Academic Journal
Authors: D. S. Mikhaylenko, S. A. Sergienko, I. N. Zaborsky, K. N. Saflullin, S. A. Serebryany, N. Yu. Safronova, M. V. Nemtsova, A. D. Kaprin, B. Ya. Alekseev, Д. С. Михайленко, С. А. Сергиенко, И. Н. Заборский, К. Н. Сафиуллин, С. А. Серебряный, Н. Ю. Сафронова, М. В. Немцова, А. Д. Каприн, Б. Я. Алексеев
Source: Cancer Urology; Том 14, № 4 (2018); 124-138 ; Онкоурология; Том 14, № 4 (2018); 124-138 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2018-14-4
Subject Terms: экспрессия генов, microsatellite instability, genetic polymorphism, mutational load, BCG therapy, somatic mutation, immunotherapy, gene expression, микросателлитная нестабильность, генетический полиморфизм, мутационная нагрузка, БЦЖ-терапия, соматическая мутация, иммунотерапия
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/894/816; Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 250 с.; Ferlay J., Soerjomataram I. Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Can-cer 2015;136(5):E359—86. DOI:10.1002/ijc.29210. PMID: 25220842.; Comperat E., Larre S., Roupret M. et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch 2015;466(5):589—94. DOI:10.1007/s00428-015-1739-2. PMID: 25697540.; Freedman N.D., Silverman D.T., Hollenbeck A.R. et al. Association between smoking and risk of bladder cancer among men and women. JAMA 2011;306(7):737— 45. DOI:10.1001/jama.2011.1142. PMID: 21846855.; Burger M., Catto J.W., Dalbagni G. et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013;63(2): 234—41. DOI:10.1016/j.eururo.2012.07.033. PMID: 22877502.; Colt J.S., Friesen M.C., Stewart P.A. et al. A case-control study of occupational exposure to metalworking fluids and bladder cancer risk among men. Occup Environ Med 2014;71(10):667—74. DOI:10.1136/oemed-2013-102056. PMID: 25201311.; Sylvester R.J., Oosterlinck W., Holmang S. et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa—pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol 2016;69(2):231—44. DOI:10.1016/j.eururo.2015.05.050. PMID: 26091833.; Abern M.R., Owusu R.A., Anderson M.R. et al. Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. J Natl Compr Canc Netw 2013;11(4): 477—84. PMID: 23584348.; Huncharek M., McGarry R., Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 2001;21(1B):765—9. PMID: 11299841.; Kaasinen E., Rintala E., Hellstrom P. et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 2002;42(2):167—74. PMID: 12160589.; Morales A., Eidinger D., Bruce A.W. Intracavitary Bacillus Calmette—Guerin in the treatment of superficial bladder tumors. J Urol 2017;197(2S):S142— 5. DOI:10.1016/j.juro.2016.10.101. PMID: 28012770.; Fuge O., Vasdev N., Allchorne P., Green J.S. Immunotherapy for bladder cancer. Res Rep Urol 2015;7:65—79. DOI:10.2147/RRU.S63447. PMID: 26000263.; Malmstrom P.U., Sylvester R.J., Crawford D.E. et al. An individual patient data metaanalysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette—Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009;56(2):247—56. DOI:10.1016/j.eururo.2009.04.038. PMID: 19409692.; Bohle A., Bock P.R. Intravesical bacille Calmette—Guerin versus mitomycin C in superficial bladder cancer: formal metaanalysis of comparative studies on tumor progression. Urology 2004;63(4):682—6. PMID: 15072879.; Гладков О.А., Матвеев В.Б., Митин Т. и др. Практические рекомендации по лекарственному лечению рака мочевого пузыря. Злокачественные опухоли: Практические рекомендации RUSSCO 2017;7:411 —20. DOI:10.18027/2224-5057-2017-7-3s2-411-420.; Берников А.Н., Волкова М.И., Корякин О.Б. и др. Рак мочевого пузыря: клинические рекомендации. Научный совет Минздрава России, 2017, 57 с. ID: КР11.; Brausi M., Oddens J., Sylvester R. et al. Side effects of Bacillus Calmette—Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC geni-to-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 2014;65(1):69—76. DOI:10.1016/j.eururo.2013.07.021. PMID: 23910233.; Redelman-Sidi G., Glickman M.S., Bochner B.H. The mechanism of action of BCG therapy for bladder cancer — a current perspective. Nat Rev Urol 2014;11(3):153—62. DOI:10.1038/nrurol.2014.15. PMID: 24492433.; Pettenati C., Ingersoll M.A. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol 2018;15(10):615—25. DOI:10.1038/s41585-018-0055-4. PMID: 29991725.; Лелявин К.Б., Дворниченко В.В. Внутрипузырная иммунотерапия вакциной BCG в комплексном лечении немышечно-инвазивного рака мочевого пузыря. Сибирский медицинский журнал 2010;(4):5—8. Russian.; Saluja M., Gilling P. Intravesical bacillus Calmette—Guerin instillation in non-muscle-invasive bladder cancer: a review. Int J Urol 2018;25(1):18—24. DOI: 10.nn/iju.13410. PMID: 28741703.; Maruf M., Brancato S.J., Agarwal P.K. Nonmuscle invasive bladder cancer: a primer on immunotherapy. Cancer Biol Med 2016;13(2):194—205. DOI:10.20892/j.issn.2095-3941.2016.0020. PMID: 27458527.; Wu C., Zhou X., Miao C. et al. Assessing the feasibility of replacing standard-dose Bacillus Calmette—Guerin immunotherapy with other intravesical instillation therapies in bladder cancer patients: a network metaanalysis. Cell Physiol Biochem 2017;41(4):1298—312. DOI:10.1159/000464432. PMID: 28278504.; Patel S.G., Cohen A., Weiner A.B., Stein-berg G.D. Intravesical therapy for bladder cancer. Expert Opin Pharmacother 2015;16(6):889—901. DOI:10.1517/14656566.2015.1024656. PMID: 25773220.; Deng X., Zhang X., Cheng Y. et al. XRCC1 polymorphisms associated with survival among Chinese bladder cancer patients receiving epirubicin and mitomycin C. Tumour Biol 2015;36(6):4591 —96. DOI:10.1007/s13277-015-3104-0. PMID: 25616696.; Deng X., Yang X., Cheng Y. et al. GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy. DOI:10.1038/srep14000. PMID: 26354850.; Mittal R.D. Gene variants in predicting BCG response to urinary bladder cancer. Indian J Clin Biochem 2012;27(1):1—5. DOI:10.1007/s12291-012-0191-1. PMID: 23277706.; Buffen K., Oosting M., Quintin J. et al. Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer. PLoS Pathog 2014;10(10):e1004485. DOI:10.1371/journal.ppat.1004485. PMID: 25356988.; Williams S.B., Kamat A.M., Mmeje C. et al. Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette— Guerin. Oncotarget 2017;8(51):88782—91. DOI:10.18632/oncotarget.21222. PMID: 29179475.; Grotenhuis A.J., Dudek A.M., Vrhaegh G.W et al. Independent replication of published germline polymorphisms associated with urinary bladder cancer prognosis and treatment response. Bladder Cancer 2016;2(1):77—89. PMID: 27376129.; Lima L., Ferreira J.A., Tavares A. et al. FASL polymorphism is associated with response to bacillus Calmette—Guerin immunotherapy in bladder cancer. Urol Oncol 2014;32(1):44.e1-7. DOI:10.1016/j.urolonc.2013.05.009. PMID: 23948181.; Ke H.L., Lin J., Ye Y. et al. Genetic variation in glutathione pathway genes predict cancer recurrence in patients treated with transurethral resection and Bacillus Calmette—Guerin instillation for nonmuscle invasive bladder cancer. Ann Surg Oncol 2015;22(12):4104—10. DOI:10.1245/s10434-015-4431-5. PMID: 25851338.; Kang H.W., Tchey D.U., Yan C. et al. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer. Urol Oncol 2014;32(4):458—65. DOI:10.1016/j.urolonc.2013.10.013. PMID: 24411789.; Lima L., Oliveira D., Ferreira J.A. et al. The role of functional polymorphisms in immune response genes as biomarkers of bacilli Calmette—Guerin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population. BJU Int 2015;116(5):753—63. DOI:10.1111/bju.12844. PMID: 24931268.; Zhang N., Jiang G., Liu X. et al. Prediction of Bacillus Calmette—Guerin response in patients with bladder cancer after transurethral resection of bladder tumor by using genetic variation based on genomic studies. Biomed Res Int 2016;2016:9859021. DOI:10.1155/2016/9859021. PMID: 27896277.; Ryk C., Koskela L.R., Thiel T. et al. Out-come after BCG treatment for urinary bladder cancer may be influenced by polymorphisms in the NOS2 and NOS3 genes. Redox Biol 2015;6:272—7. DOI:10.1016/j.redox.2015.08.008. PMID: 26298202.; Chiong E., Kesavan A., Mahendran R. et al. NRAMP1 and hGPX1 gene poly-morphism and response to Bacillus Calmette—Guerin therapy for bladder cancer. Eur Urol 2011;59(3):430—7. DOI:10.1016/j.eururo.2010.11.031. PMID: 21163569.; Lenormand C., Couteau J., Nouhaud F.X. et al. Predictive value of NRAMP1 and HGPX1 gene polymorphism for maintenance BCG response in nonmuscle-invasive bladder cancer. Anticancer Res 2016;36(4):1737—43. PMID: 27069153.; Wei H., Kamat A., Chen M. et al. Associa¬tion of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette—Guerin. PLoS One 2012;7(6):e38533. DOI:10.1371/journal.pone.0038533. PMID: 22701660.; Kandimalla R., van Tilborg A.A., Zwarthoff E.C. DNA methylation-based biomarkers in bladder cancer. Nat Rev Urol 2013;10(6):327—35. DOI:10.1038/nrurol.2013.89. PMID: 23628807.; Agundez M., Grau L., Palou J. et al. Evaluation of the methylation status of tumour suppressor genes for predicting Bacillus Calmette—Guerin response in patients with T1G3 high-risk bladder tumours. Eur Urol 2011;60(1):131—40. DOI:10.1016/j.eururo.2011.04.020. PMID: 21514719.; Husek P., Pacovsky J., Chmelarova M. et al. Methylation status as a predictor of intravesical Bacillus Calmette—Guerin (BCG) immunotherapy response of high grade non-muscle invasive bladder tumor. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2017;161(2):210—6. DOI:10.5507/bp.2017.008. PMID: 28344356.; Zuiverloon T.C., Nieuweboer A.J., Vekony H. et al. Markers predicting response to bacillus Calmette—Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 2012;61(1):128—45. DOI:10.1016/j.eururo.2011.09.026. PMID: 22000498.; Poli G., Cochetti G., Boni A. et al. Characterization of inflammasome-related genes in urine sediments of patients receiving intravesical BCG therapy. Urol Oncol 2017;35(12):674.e19—24. DOI:10.1016/j.urolonc.2017.08.004. PMID: 28888400.; Rahmat J.N., Esuvaranathan K., Mahendran R. Bacillus Calmette—Guerin induces rapid gene expression changes in human bladder cancer cell lines that may modulate its survival. Oncol Lett 2018;15(6):9231—41. DOI:10.3892/ol.2018.8462. PMID: 29844825.; Mano R., Zilber S., Di Natale R.G. et al. Heat shock proteins 60 and 70 are associated with longterm outcome of T1-stage high-grade urothelial tumors of the bladder treated with intravesical Bacillus Calmette—Guerin immunotherapy. Urol Oncol 2018;36(12):531.e9—17. DOI:10.1016/j.urolonc.2018.09.007. PMID: 30337218.; He Y., Wang N., Zhou X. et al. Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review. BMJ Open 2018;8(4):e019635. DOI:10.1136/bmjopen-2017-019635. PMID: 29666128.; Wang C., Li A., Yang S. et al. CXCL5 promotes mitomycin C resistance in non-muscle invasive bladder cancer by activating EMT and NF-KB pathway. Biochem Biophys Res Commun 2018;498(4): 862—8. DOI:10.1016/j.bbrc.2018.03.071. PMID: 29545183.; Xu T., Qin L., Zhu Z. et al. MicroRNA-31 functions as a tumor suppressor and increases sensitivity to mitomycin-C in urothelial bladder cancer by targeting integrin a5. Oncotarget 2016;7(19):27445—57. DOI:10.18632/oncotarget.8479. PMID: 27050274.; Kamat A.M., Li R., O’Donnell M.A. et al. Predicting response to intravesical Bacillus Calmette-Guerin immunotherapy: are we there yet? A systematic review. Eur Urol 2018;73(5):738—48. DOI:10.1016/j.eururo.2017.10.003. PMID: 29055653.; Sanguedolce F., Cormio A., Massenio P. et al. Altered expression of HER-2 and the mismatch repair genes MLH1 and MSH2 predicts the outcome of T1 high-grade bladder cancer. J Cancer Res Clin Oncol 2018;144(4):637—44. DOI:10.1007/s00432-018-2593-9. PMID: 29362915.; Abbosh P.H., Plimack E.R. Molecular and clinical insights into the role and significance of mutated DNA repair genes in bladder cancer. Bladder Cancer 2018;4(1):9—18. DOI:10.3233/BLC-170129. PMID: 29430503.; Mouw K.W. DNA repair pathway alterations in bladder cancer. Cancers (Basel) 2017;9(4):E28. DOI:10.3390/cancers9040028. PMID: 28346378.; Liem E.I., Baard J., Cauberg E.C. et al. Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette-Guerin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer. Med Oncol 2017;34(10):172. DOI:10.1007/s12032-017-1033-z. PMID: 28866819.; Grivas P.D., Melas M., Papavassiliou A.G. The biological complexity of urothelial carcinoma: insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches. Semin Cancer Biol 2015;35:125-32. DOI:10.1016/j.semcancer.2015.08.006. PMID: 26304731.; Михайленко Д.С., Немцова М.В. Точковые соматические мутации в развитии рака мочевого пузыря: ключевые события канцерогенеза, диагностические маркеры и мишени для терапии. Урология 2016;(1):100—5. Russian; Ren R., Tyryshkin K., Graham C.H. et al. Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance. Oncotarget 2017;8(41):70982—1001. DOI:10.18632/oncotarget.20237. PMID: 29050337.; Meeks J.J., Carneiro B.A., Pai S.G. et al. Genomic characterization of high-risk non-muscle invasive bladder cancer. Oncotarget 2016;7(46):75176—84. DOI:10.18632/oncotarget.12661. PMID: 27750214.; Pietzak E.J., Bagrodia A., Cha E.K. et al. Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur Urol 2017;72(6):952—9. DOI:10.1016/j.eururo.2017.05.032. PMID: 28583311.; Pang K.H., Esperto F., Noon A.P. et al. Opportunities of next-generation sequencing in non-muscle invasive bladder cancer outcome prediction. Transl Androl Urol 2017;6(6):1043—8. DOI:10.21037/tau.2017.10.04. PMID: 29354491.; Scott S.N., Ostrovnaya I., Lin C.M. et al. Next-generation sequencing of urine specimens: a novel platform for genomic analysis in patients with non-muscleinvasive urothelial carcinoma treated with bacille Calmette—Guerin. Cancer Cytopathol 2017;125(6):416—26. DOI:10.1002/cncy.21847. PMID: 28339163.; Волкова М.И., Гриднева Я.В., Ольшанская А.С. Иммунотерапия уротелиального рака: реалии и перспективы. Онкоурология 2017;13(4):16—24. DOI:10.17650/1726-9776-2017-13-4-16-24.; Dietrich B., Srinivas S. Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease. Res Rep Urol 2018;10:7—16. DOI:10.2147/RRU.S125635. PMID: 29417045.; Горелов А.И., Симбирцев А.С., Журавский Д.А., Горелова А.А. Ингибиторы PD-1/PD-L1 в лечении рака мочевого пузыря: от медиатора иммунного ответа к таргетной терапии. Урологические ведомости 2018;8(2):64—72. DOI:10.17816/uroved8264-72.; Huang Y., Zhang S.D., McCrudden C. et al. The prognostic significance of PD-L1 in bladder cancer. Oncol Rep 2015;33(6):3075—84. DOI:10.3892/or.2015.3933. PMID: 25963805.; Chang L., Chang M., Chang H.M., Chang F. Microsatellite instability: a predictive biomarker for cancer immunotherapy. Appl Immunohistochem Mol Morphol 2018;26(2):e15—21. DOI:10.1097/PAI.0000000000000575. PMID: 28877075.; Aggen D.H., Drake C.G. Biomarkers for immunotherapy in bladder cancer: a moving target. J Immunother Cancer 2017;5(1):94. DOI:10.1186/s40425-017-0299-1. PMID: 29157296.; Kim H.S., Seo H.K. Immune checkpoint inhibitors for urothelial carcinoma. Investig Clin Urol 2018;59(5):285—96. DOI:10.4111/icu.2018.59.5.285. PMID: 30182073.; Felsenstein K.M., Theodorescu D. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. Nat Rev Urol 2018;15(2):92—111. DOI:10.1038/nrurol.2017.179. PMID: 29133939.; Wezel F., Vallo S., Roghmann F. et al. Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer? Transl Androl Urol 2017;6(6):1067—80. DOI:10.21037/tau.2017.09.18. PMID: 29354494.; Udall M., Rizzo M., Kenny J. et al. PD-L1 diagnostic tests: a systematic lit-erature review of scoring algorithms and test-validation metrics. Diagn Pathol 2018;13(1):12. DOI:10.1186/s13000-018-0689-9. PMID: 29426340.; Hashizume A., Umemoto S., Yokose T. et al. Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette—Guerin. Oncotarget 2018;9(75):34066—78. DOI:10.18632/oncotarget.26122. PMID: 30344922.; Wang Y., Liu J., Yang X. et al. Bacillus Calmette—Guerin and anti-PD-L1 combination therapy boosts immune response against bladder cancer. Onco Targets Ther 2018;11:2891 —9. DOI:10.2147/OTT.S165840. PMID: 29844686.; Stenehjem D.D., Tran D., Nkrumah M.A., Gupta S. PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. Onco Targets Ther 2018;11:5973— 89. DOI:10.2147/OTT.S135157. PMID: 30275703.; Rouanne M., Roumiguie M., Houede N. et al. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. World J Urol 2018;36(11):1727—40. DOI:10.1007/s00345-018-2332-5. PMID: 29855698.; https://oncourology.abvpress.ru/oncur/article/view/894
-
8Academic Journal
Authors: Костев, Ф. И., Соколов, В. Н., Бондарь, А. В., Чистяков, Р. С., Kostyev, F. I., Sokolov, V. N., Bondar, O. V., Chystiakov, R. S.
Subject Terms: мышечно-неинвазивный рак мочевогопузыря, внутрипузырная гипертермическая химиотерапия, БЦЖ терапия, non-muscle-invasive bladder cancer, intravesical hyperthermic chemotherapy, BCG therapy
File Description: application/pdf
Relation: Сравнительная оценка качества жизни пациентов мышечнонеинвазивным раком мочевого пузыря, получающих адъювантую внутрипузырную терапию / Ф. И. Костев, В. Н. Соколов, А. В. Бондарь, Р. С. Чистяков // German International Journal of Modern Science. – 2021. – № 4. – С. 32–37.; https://repo.odmu.edu.ua:443/xmlui/handle/123456789/8744
Availability: https://repo.odmu.edu.ua:443/xmlui/handle/123456789/8744
-
9Academic Journal
Authors: Фигурин, К.
Subject Terms: МЫШЕЧНО-НЕИНВАЗИВНЫЙ РАК МОЧЕВОГО ПУЗЫРЯ, ВАКЦИНА БЦЖ, ВНУТРИПУЗЫРНАЯ БЦЖ-ТЕРАПИЯ, ЭФФЕКТИВНОСТЬ, ПОБОЧНЫЕ ЯВЛЕНИЯ
File Description: text/html
-
10Academic Journal
Authors: Замятин, А. В., Магер, В. О., Берзин, С. А., Рожин, А. И.
Subject Terms: ПОВЕРХНОСТНЫЙ РАК МОЧЕВОГО ПУЗЫРЯ, ВНУТРИПУЗЫРНАЯ ХИМИОТЕРАПИЯ, БЦЖ-ТЕРАПИЯ
File Description: application/pdf
Relation: Уральский медицинский журнал. 2007. Т. 37, № 9.; http://elib.usma.ru/handle/usma/17422
Availability: http://elib.usma.ru/handle/usma/17422
-
11
-
12Academic Journal
Source: Онкоурология.
Subject Terms: МЫШЕЧНО-НЕИНВАЗИВНЫЙ РАК МОЧЕВОГО ПУЗЫРЯ, ВАКЦИНА БЦЖ, ВНУТРИПУЗЫРНАЯ БЦЖ-ТЕРАПИЯ, ЭФФЕКТИВНОСТЬ, ПОБОЧНЫЕ ЯВЛЕНИЯ, 03 medical and health sciences, 0302 clinical medicine, 3. Good health
File Description: text/html
